Status:
WITHDRAWN
Bupivacaine Liposome Serrate Anterior Plane Block vs Traditional Thoracic Paravertebral Block
Lead Sponsor:
Shiyou Wei
Conditions:
Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
In this study, patients will receive bupivacaine liposome serratus anterior plane block or ropivacaine paraspinal block to manage postoperative pain. Follow-up visits will be conducted to investigate ...
Detailed Description
Extensive research suggests that paravertebral block can replace thoracic epidural anesthesia as the "gold standard" for thoracic surgery pain relief. However, this technique is more challenging than ...
Eligibility Criteria
Inclusion
- Elective unilateral thoracoscopic lung surgery.
- Age between 18 and 75 years old.
- American Society of Anesthesiologists (ASA) classification I to III.
Exclusion
- Contraindications to nerve block: puncture site infection, local anesthetic allergy, coagulation disorders or risk of bleeding.
- Hepatic or renal dysfunction.
- Pregnant, breastfeeding, possibility of pregnancy or planned pregnancy.
- Use of analgesic drugs before surgery or history of chronic pain or opioid abuse.
- Patients who refuse to participate.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 3 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06135545
Start Date
October 1 2023
End Date
October 3 2023
Last Update
January 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200082